Cargando…
The Inflation Reduction Act: A boon for the generic and biosimilar industry
WHAT IS KNOWN AND OBJECTIVE: After more than a year of negotiation, a $740 billion climate and health care bill known as The Inflation Reduction Act (IRA) became law on 16 August 2022. In addition to its impact on the environment, job creation and reducing inflation, a key focus is to reduce the bur...
Autor principal: | Niazi, Sarfaraz K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828046/ https://www.ncbi.nlm.nih.gov/pubmed/36207987 http://dx.doi.org/10.1111/jcpt.13783 |
Ejemplares similares
-
Molecular Biosimilarity—An AI-Driven Paradigm Shift
por: Niazi, Sarfaraz K.
Publicado: (2022) -
No two classes of biosimilars: Urgent advice to the US Congress and the FDA
por: Niazi, Sarfaraz K.
Publicado: (2022) -
A Critical Analysis of the FDA’s Omics-Driven Pharmacodynamic Biomarkers to Establish Biosimilarity
por: Niazi, Sarfaraz K.
Publicado: (2023) -
The FDA’s New Guideline “Generally Accepted Scientific Knowledge” (GASK): An Opportunity to Expedite the Approval of Biosimilars
por: Niazi, Sarfaraz K.
Publicado: (2023) -
Biosimilars Adoption: Recognizing and Removing the RoadBlocks
por: Niazi, Sarfaraz K
Publicado: (2023)